Phenolaeis was established in 2011 and was granted a worldwide license by the Malaysian Palm Oil Board (MPOB) to a portfolio of patents related to the isolation, formulation and methods of use of a water-soluble material produced from the fruit of the oil palm tree. The water-soluble Palm Fruit Bioactives Complex (PFBc) produced from the fruit of the oil palm tree has been subjected to extensive scientific study over the past 15 years. The fundamental technology development was led by MPOB which worked in collaboration with scientists from world-renowned universities and institutions such as MIT (Cambridge, MA), Brigham and Women’s Hospital (Boston, MA), Brandeis University (Boston, MA), Wayne State University (Detroit, MI), and CSIRO in Australia. In December 2017, Phenolaeis completed a Joint Venture Partnership with Entorno Agroforestal and Evergreen Health to form Phenolaeis Mexico S.A.P.I. de C.V. Phenolaeis’ operational management is headquartered in Cambridge, MA USA.
Kevin L. Ohashi, PhD, MBA
Chief Executive Officer
Dr. Ohashi has over 15 years of experience developing and leading Life Science technology teams and companies. Kevin co-founded and was Managing Director of Bay Innovation Group (BIG). BIG founded venture backed companies Cayenne Medical, Inc. (Sports Medicine) and nContact, Inc. (Atrial Fibrillation). He is a founder and Managing Partner at Pond Capital and was a Senior Associate at The Vertical Group. He serves on the Board of Directors for Direct Dermatology, Inc. (Dermatology), DRP Medical, Inc. (Acute Kidney Injury), Tauten, Inc. (Sport Fishing) and MicroVascular Tissues (Regenerative Medicine).
Thomas J. Slater
Chief Business Officer and Senior Vice President Sales and Marketing
Mr. Slater has over 30 years of experience in sales, marketing and business development for nutraceutical, biotechnology and pharmaceutical companies. Mr. Slater previously served as Vice President of International & Alliance Management for Cubist Pharmaceuticals, Inc. where he helped to launch Cubicin globally, a hospital IV antibiotic for MRSA. In his role as Vice President of Genzyme Corporation, Mr. Slater led the pharmaceutical and fine chemical business unit. He was responsible for all fine chemical product lines including the marketing and sales platform for Melatonin (brand name: MelaPure). Previous to Genzyme, Mr. Slater managed new product introductions for P. Leiner Corporation which included all nutritional products and Rx to OTC switches. Mr. Slater also held positions of increasing responsibility in Hoffmann LaRoche’s Human Nutrition Division.
Joseph De Angelo
Head of Research & Clinical Programs
Mr. De Angelo has 27 years of experience developing and leading Life Science technology teams and companies. Mr. De Angelo is the founder and Principal at Scizyg, performing consulting and contract product development in biotechnology and biopharmaceuticals. He was Chief Development Officer for Curacyte AG/Apex Bioscience, Inc. Mr. De Angelo founded and held positions as Chief Scientific Officer and VP of Research for Apex Biosciences as well as serving on the Board of Directors. He managed the development and construction of plant facilities and development programs involving fermentation and downstream processing